Media release

From: Pasifika Medical Association Group

The recent announcement by the Honourable David Seymour approving the clinical use of psilocybin-assisted therapy for treatment-resistant depression (TRD) has placed New Zealand on the global map, joining a handful of countries at the forefront of psychedelic medicine. There has been intense public, professional and media interest; stories in the New York Times, Time Magazine, Stuff, and Radio New Zealand have captured imaginations and raised expectations across the country. But with this attention comes a significant challenge: to ensure that this emerging treatment does not become the preserve of the privileged few but is available equitably to all New Zealanders who need it.